Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Graf

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
Health Policy (Amsterdam, Netherlands)|December 5, 2021
Amortization of gene replacement therapies: A health policy analysis exploring a mechanism for mitigating budget impact of high-cost treatmentsMonique Dabbous, Mondher Toumi, Steven Simoens, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|August 15, 2020
HTA methodology and value frameworks for evaluation and policy making for cell and gene therapiesDoug Coyle, Isabelle Durand-Zaleski, Jasmine Farrington, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 25, 2016
Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in EuropeAris Angelis, Panos Kanavos, Julio López-Bastida, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 4, 2016
Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in EuropeJulio López-Bastida, Renata Linertová, Juan Oliva-Moreno, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 14, 2016
Social/economic costs and health-related quality of life in patients with fragile X syndrome in EuropeKarine Chevreul, Coralie Gandré, Karen Berg Brigham, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 5, 2016
Social/economic costs and health-related quality of life in patients with histiocytosis in EuropeGeorgi Iskrov, Itziar Astigarraga, Rumen Stefanov, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 10, 2016
Social/economic costs and health-related quality of life in patients with cystic fibrosis in EuropeKarine Chevreul, Morgane Michel, Karen Berg Brigham, et al.
Health Policy (Amsterdam, Netherlands)|September 6, 2012
Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD studyRenata Linertová, Pedro Serrano-Aguilar, Manuel Posada-de-la-Paz, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 4, 2016
Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in EuropeMarianna Cavazza, Yllka Kodra, Patrizio Armeni, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 7, 2016
Social/economic costs and quality of life in patients with haemophilia in EuropeMarianna Cavazza, Yllka Kodra, Patrizio Armeni, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Health Policy (Amsterdam, Netherlands)|December 5, 2021
Amortization of gene replacement therapies: A health policy analysis exploring a mechanism for mitigating budget impact of high-cost treatmentsMonique Dabbous, Mondher Toumi, Steven Simoens, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|August 15, 2020
HTA methodology and value frameworks for evaluation and policy making for cell and gene therapiesDoug Coyle, Isabelle Durand-Zaleski, Jasmine Farrington, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 25, 2016
Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in EuropeAris Angelis, Panos Kanavos, Julio López-Bastida, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 4, 2016
Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in EuropeJulio López-Bastida, Renata Linertová, Juan Oliva-Moreno, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 14, 2016
Social/economic costs and health-related quality of life in patients with fragile X syndrome in EuropeKarine Chevreul, Coralie Gandré, Karen Berg Brigham, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 5, 2016
Social/economic costs and health-related quality of life in patients with histiocytosis in EuropeGeorgi Iskrov, Itziar Astigarraga, Rumen Stefanov, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 10, 2016
Social/economic costs and health-related quality of life in patients with cystic fibrosis in EuropeKarine Chevreul, Morgane Michel, Karen Berg Brigham, et al.
Health Policy (Amsterdam, Netherlands)|September 6, 2012
Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD studyRenata Linertová, Pedro Serrano-Aguilar, Manuel Posada-de-la-Paz, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 4, 2016
Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in EuropeMarianna Cavazza, Yllka Kodra, Patrizio Armeni, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 7, 2016
Social/economic costs and quality of life in patients with haemophilia in EuropeMarianna Cavazza, Yllka Kodra, Patrizio Armeni, et al.
Pageof 11